Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
ApexOnco Front Page
Recent articles
The companies press on with vilastobart and IMPT-314... up to a point.
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
The private group taps DualityBio for an EGFR x HER3 ADC.
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
A new phase 3 study will test Anktiva in PD-(L)1-relapsed lung cancer.
Subcutaneous Opdivo joins Tecentriq Hybreza to round out 2024.
